

Image 2:

ITEMS	TOTAL SAMPLE N=218	ALCOHOL INDUCED PSYCHOTIC DISORDER N=23	PSYCHOSTIMULANTS INDUCED PSYCHOTIC DISORDER N=71	CANNABIS INDUCED PSYCHOTIC DISORDER N=116	F	P
AGE AT HOSPITAL ADMISSION	33,89 dsx 12,21	45,42 dsx 13,64	35,41 dsx 11,91	29,87 dsx 9,63	25,29	p<0,01
AGE AT ONSET	28,09 dsx 10,97	33,28 dsx 12,90	30,38 dsx 11,58	25,20 dsx 9,07	9,08	p<0,01
DURATION OF ILLNESS	5,83 dsx 8,81	11,83 dsx 14,64	4,97 dsx 7,42	4,74 dsx 6,75	8,43	p<0,01
NUMBER OF HOSPITAL ADMISSIONS MISSING=8	2,18 dsx 4,73	3,71 dsx 7,05	1,17 dsx 1,48	2,38 dsx 5,13	3,36	0,04
MODIFIED SAS PERSONS SCALE	2,49 dsx 1,09	3,16 dsx 1,21	2,29 dsx 1,02	2,42 dsx 1,04	6,19	p<0,01
URIA	27,64 dsx 9,08	31,56 dsx 11,03	27,92 dsx 10,23	26,10 dsx 7,03	3,79	0,03
FAI ACQU	112,96 dsx 77,20	159,13 dsx 112,31	102,55 dsx 65,15	103,13 dsx 64,29	3,69	0,03
CHOLESTEROL	170,72 dsx 44,23	192,92 dsx 49,51	169,00 dsx 53,78	165,31 dsx 34,16	3,98	0,02
ALBUMIN	4,42 dsx 0,46	4,38 dsx 0,59	4,30 dsx 0,44	4,51 dsx 0,40	2,74	0,07

Image 3:

ITEMS	TOTAL SAMPLE N=218	PSYCHOSTIMULANTS INDUCED PSYCHOTIC DISORDER N=71	CANNABIS INDUCED PSYCHOTIC DISORDER N=116	F	P
AGE AT HOSPITAL ADMISSION	33,89 dsx 12,21	35,41 dsx 11,91	29,87 dsx 9,63	F=12,13	p=0,00
AGE AT ONSET	28,09 dsx 10,97	30,38 dsx 11,58	25,20 dsx 9,07	F=10,87	p=0,00
NUMBER OF HOSPITAL ADMISSIONS MISSING=8	2,18 dsx 4,73	1,17 dsx 1,48	2,38 dsx 5,13	F=3,59	p=0,06
BPRS	42,89 dsx 12,12	41,27x12,04	44,96x12,16	F=3,21	p=0,05
ERYTHROCYTES	4,86 dsx 0,57	4,74x0,57	4,94x0,54	F=4,94	p=0,03
HEMOGLOBIN	14,49 dsx 1,55	14,15x1,62	14,73x1,44	F=5,49	p=0,02
ALBUMIN	4,42 dsx 0,46	4,30x0,44	4,51x0,40	F=6,22	p=0,01
GAMMA-GT	43,97 dsx 12,13	37,38x 60,32	24,12x18,83	F=4,08	p=0,05

Conclusions: For each considered subgroups, we identified the following features. Alcohol induced psychotic syndrome: higher age of onset and age of hospital admission, higher cholesterol and hurea levels, , high comorbidity with medical conditions anxiety/depression, low social functioning, higher suicidal risk;; higher hospitalization rate. Cannabis induced psychotic syndrome: higher hemoglobin and albumin levels, more severe psychiatric symtoms (BPRS), higher smoking rates. Psychostimulants induced psychotic syndrome: higher multi-drug abuse risk. We could assume that according to this consideration the treatment protocols for each of these subgroups should be tailored according to their specific features.

Disclosure of Interest: None Declared

EPP0808

Changing Perspective in Dual Disorders: Substance Use, Personality Disorder, and Psychosis

H. Becerra Darriba

Psychiatry, Osasunbidea, Tudela, Spain
doi: 10.1192/j.eurpsy.2023.1093

Introduction: Dual disorders constitute a clinical entity with increasing current prevalence (Köck *et al.* Front Psychiatry 2022; 24 13). There is frequent comorbidity between psychotic spectrum disorders and substance use disorders, which hinders both psychopathological stability and the approach to addictive behaviors (Fleury *et al.* Adm Policy Ment Health 2022; 20).

Objectives: The aim of this study is to describe the clinical and sociodemographic characteristics of the consumption pattern of patients diagnosed with psychosis in outpatient follow-up.

Methods: A cross-sectional study was designed with 42 users treated at the mental health center between 2019 and 2021, aged between 18 and 65 years, who had consumed alcohol, cannabis, and/or stimulants (amphetamines or cocaine), with a diagnosis of a comorbid psychotic spectrum disorder for over 3 years. A

descriptive analysis of the prevalence of consumption of each predominant substance was carried out, as well as the sociodemographic and clinical characteristics were collected through a semi-structured interview. Statistical analyzes were performed using SPSS v23.0 (significance p<0.05).

Results: The predominant user profile was a man (85.7%), with a mean age of around 29 years, single (83.3%), with family support (52.4%), resident in rural areas (92.8%), with unqualified employment (57.1%) and primary studies (60%). Cannabis was the predominant substance (80.9%), followed by amphetamines (71.4%), with polydrug use of both in 78.6% of cases. A significant association was found between this combined use of substances, the relapse rate and the presence of comorbid personality disorder.

Conclusions: The paradigm of substance use in psychotic disorders has evolved towards comorbidity with polydrug use and confluence with personality disorders.

Disclosure of Interest: None Declared

EPP0809

Drugs and high hospitalization rate: are they related?

I. M. Figueiredo*, I. Cargaleiro and M. Nascimento

Hospital Centre of Psychiatry of Lisbon, Lisbon, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1094

Introduction: Substance use continues to be an important problem among mental health patients either as main diagnosis or as comorbidity. Acute care visits, including emergency department visits and hospitalizations, related to substance use disorders (SUD) are increasing and can be opportunities to engage individuals to get proper treatment (Suen LW *et al.* J Gen Intern Med 2022; 37(10):2420–2428). Both mental disorders and SUD lead to subsequent chronic physical conditions, premature death, suicide or overdose (Bennett AC. Public Health Rep 2019; 134(1):17-26) that can be accidental or not. 24% to 32% of patients with Substance Induced Psychosis develop later a schizophrenia spectrum disorder or bipolar disorder (Starzer MSK *et al.* Am J Psychiatry 2018;175(4):343–350) leading to a chronic use of medication and, in several instances, to a necessity of psychiatric in-patient treatment with long hospital stays and high readmission rates (Khan S. Health Reports (2017) 28(8)3-8).

Objectives: Our goal was to analyze if substance use is associated with higher psychiatric hospitalization rates.

Methods: An independent-samples t-test was run to determine if there were more hospitalizations among patients with substance use. Afterwards, the Cohen’s D was calculated to measure the effect size and to see the magnitude of the experimental effect.

Results: A sample of 2604 in-patient treatment episodes was used. The sample had 1696 female patients, 908 male patients and 823 patients had substance use. We found that patients with substance use had a statistically significant higher hospitalization rate (6.82±5.27) than the ones without it (5.32±4.84), t(1483) =6.945, p<0.001. Cohen’s effect size value (d=.30) suggested a small practical significance.

Conclusions: Our findings go mainly accordingly the literature; we found a significant effect of drugs on readmission rates (Böckmann V *et al.* Front Psychiatry 2019; 10:828) but we might have thought it would be bigger. That could be explain by undiagnosed substance use (refusal to admit the use, drugs not detected on lab tests, not

requesting toxic lab tests) or higher sample percentage of confounding comorbid diagnoses.

However, is undoubtable the several risks that drugs bring to our health and so the authors aim to raise awareness among the medical community to the importance being alert for signs of use or psychiatric symptoms to avoid reaching a no turning point. It's known that doctors frequently fail to diagnose SUD in hospitalized patients and given the linkage between use of certain substances and particular medical reasons for admission, it would be well-advised to search for SUD in certain admission diagnoses (Weintraub E *et al.* Am J Addict 2001;10(2):167-77). Knowledge of substance use behavior may help reducing relapse rates and to reduce the risk of developing a SUD (Andersson HW *et al.* Nordic Journal of Psychiatry, 75:3, 160-169).

Disclosure of Interest: None Declared

EPP0810

Alcohol related dementia and Brain Imaging

I. Faria*, J. Galiano, B. Wildenberg, T. Silva and C. Silva

Psychiatry, Coimbra Hospital and University Centre, Coimbra, Portugal

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1095

Introduction: Alcohol is considered a social evil worldwide owing to its vast array of associated problems and complications, which may manifest in medical, legal or social domains. Excessive and prolonged alcohol use may lead to permanent structural and functional damage to the brain. The evidence from neuroimaging, neuropathological reports and autopsy evaluations suggest some degree of brain pathology in individuals diagnosed with an alcohol related disorder.

Objectives: The aim of this study is to characterize the structural imaging findings on computed tomography (CT) and magnetic resonance (MR) imaging of our sample and provide an overview of the literature on the subject.

Methods: Retrospective observational study with inpatients of Coimbra Hospital and University Centre (CHUC), who had alcohol use disorder diagnosis associated with dementia or cognition deficit. Patients were admitted from 2017 to 2021 and submitted to neuroimaging: CT and MR. Data was collected in May 2021 at informatic system.

Results: Among 38 participants, the median age was 64 years; 86,8% were male. 35 realize CT, 34 with alterations: 23 with microvascular lesions, 17 with cortical atrophy, 8 with white matter hypodensities and 7 with subcortical atrophy. From all patients, only 14 realize MR, 13 with alterations, the most common vascular leukoencephalopathy and cortical atrophy.

Conclusions: Our results support the hypothesis of neuroimaging changes resulting from alcohol consumption. The severity of alcohol dependence also correlates with neuropathophysiological and neuroimaging changes. Volume shrinkage, altered glucose metabolism and perfusion along with evidence of markedly decreased neuron density are commonly reported. The evidence of neuro-circuit disturbances is seen in form of significant loss of white matter (most prominent in the prefrontal cortex, cerebellum and corpus callosum) on functional imaging. Greater cognitive impairment has been associated with multiple and repeated withdrawal due to greater neuronal damage, and can limit the psychotherapeutic

intervention, the adherence to pharmacological therapy and abstinence maintenance. The sheer presence of alcohol use disorder should encourage a neuroimaging evaluation.

Disclosure of Interest: None Declared

EPP0811

The PANDA Unit: Responding to complexity and comorbidity in acute mental health

J. Brett^{1*}, J. Huber², G. Aguirrebarrena³ and P. T. Preisz⁴

¹Clinical Pharmacology, St. Vincents Hospital; ²Mental Health;

³Emergency Medicine, St. Vincent's Hospital and ⁴Emergency Medicine, St. Vincents Hospital, Sydney, Australia

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1096

Introduction: Acute mental health presentations such as suicidality or psychosis are frequently accompanied by intoxication, substance use disorder, deliberate self-poisoning and social crises. There is a need to break down silos and provide integrated multi-disciplinary acute care for such individuals.

Objectives: Here we describe outcomes of the Psychiatry And Drug And Alcohol (PANDA) Unit, a unique physical space collocated with the emergency department (ED) along with a unique model of care, providing multidisciplinary care to individuals presenting with acute mental health concerns plus complex comorbidity.

Methods: A description of the PANDA model of care and Service characteristics along with process and outcome measures across the first 12 months that the PANDA Unit was operational. These include number of patients admitted, patient demographics and characteristics, length of stay, referral destinations and impact on the occurrence of behavioural disturbance across the ED.

Results: PANDA opened in November 2020 and since then has admitted an average of 122 patients per month (15% Aboriginal) with an average bed occupancy of 79% and average length of stay of 1.3 days. An average of 12% of patients were scheduled under the mental health act and an average of two patients were stepped down from ICU each month, with the remainder being admitted via the ED. An average of 80.7% of these were discharged home directly while 7.2% were transferred for inpatient withdrawal management and 8.9% to inpatient mental health services. The top three substances of concern were alcohol methamphetamine and heroin and an average of 16.5% of people reported injecting drugs in the prior 3 months. An average of 37.8% patients had been seen by an emergency physician and admitted to the PANDA Unit within 4 hours, one of the best performing units hospital-wide. In the 6 months prior to PANDA becoming operational there was a median of 20 episodes of behavioural disturbance requiring restraint per month across the ED. This dropped to 12 episodes in the six months following the PANDA Unit opening.

Conclusions: The PANDA Unit model of care has proven feasible to implement and has made a positive impact on a previously underserved patient population. It has also contributed to improving the integration of care for mental health patients with comorbidity as well as reducing behavioural disturbance and improving patient flow across the emergency department.

Disclosure of Interest: None Declared